Filing Flows › Mimedx Group (MDXG) › Q2 2026 › vs Q2 2025
Mimedx Group (MDXG) Q2 2026 vs Q2 2025 (year over year)
Mimedx Group's revenue fell $34.2M (-35%) from $98.6M in Q2 2025 to $64.4M in Q2 2026. The biggest changes: Wound −$39.4M (-61%); Surgical +$5.2M (+15%).
Mimedx Group, Q2 2026: revenue $64.4M (-35% year over year), operating margin -28.7%, net loss $14.8M, operating cash flow −$10.0M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Surgical | $39.3M | $34.1M | $5.2M | +15% |
| Wound | $25.1M | $64.5M | −$39.4M | -61% |
| Revenue | $64.4M | $98.6M | −$34.2M | -35% |
| Other income, net | $686K | $637K | $49K | +8% |
| Income tax benefit | $2.9M | −$3.4M | $6.3M | — |
| Net loss | $14.8M | −$9.6M | $24.5M | — |
| Costs & expenses | $82.8M | $99.2M | −$16.4M | -17% |
| Operating costs | $82.8M | $86.2M | −$3.4M | -4% |
| Cost of revenue | $20.0M | $18.7M | $1.3M | +7% |
| Research & development | $2.8M | $3.3M | −$526K | -16% |
| Operating cash sources | $14.8M | −$9.6M | $24.5M | — |
| Depreciation & amortization | $732K | $658K | $74K | +11% |
| Share-based compensation | $903K | $4.8M | −$3.8M | -81% |
| Working capital & other | $3.2M | −$609K | $3.8M | — |
| Cash used in operations | $10.0M | −$14.4M | $24.4M | — |
| Net loss absorbed | $14.8M | −$9.6M | $24.5M | — |
Questions
How much did Mimedx Group's revenue grow year over year in Q2 2026?
Mimedx Group's revenue fell $34.2M (-35%) from $98.6M in Q2 2025 to $64.4M in Q2 2026.
What drove Mimedx Group's revenue change in Q2 2026?
Wound −$39.4M (-61%); Surgical +$5.2M (+15%).